Nitric oxide as a double-edged sword in pulmonary viral infections: Mechanistic insights and potential therapeutic

Mohammad Masood1, Prithvi Singh2, Daaniyaal Hariss3

  • 1Department of Biotechnology, Faculty of Natural Sciences, Jamia Millia Islamia, New Delhi 110025, India.

Gene
|January 8, 2024
PubMed

Insights

Nitric oxide (NO) shows potential in treating COVID-19 by inhibiting SARS-CoV-2 replication and improving oxygenation. Inhaled NO may reduce mechanical ventilation needs in patients with coronavirus disease 2019.

Area of Science:

  • Biochemistry and Molecular Biology
  • Immunology
  • Pulmonology

Background:

  • Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes COVID-19, necessitating novel therapeutic strategies.
  • Nitric oxide (NO) is a signaling molecule with critical roles in cardiovascular and pulmonary functions, immunity, and neurotransmission.
  • Dysregulation of NO production is implicated in various diseases, including cardiovascular disease, pulmonary hypertension, and asthma.

Purpose of the Study:

  • To review the molecular targets, diagnostic potential, and therapeutic applications of nitric oxide (NO) in COVID-19.
  • To explore the mechanisms of NO action in COVID-19 pathogenesis and its potential as an inhaled therapy.
  • To identify key pathways and the significance of Nitric Oxide Synthase (NOS) isoforms in COVID-19 using bioinformatics.

Main Methods:

  • Literature review focusing on NO donors, inhaled NO, and NO's role in inflammation and asthma.
  • Bioinformatic analysis of gene ontology terms (biological process, molecular function, cellular compartment) for NOS1, NOS2, and NOS3.
  • Transcriptomics analysis comparing COVID-19 and pulmonary hypertension cohorts with controls to assess NOS isoform expression.

Main Results:

  • NO donors may inhibit SARS-CoV-2 replication; inhaled NO shows promise for improving oxygenation in COVID-19 patients.
  • NO is associated with regulating guanylate cyclase activity, arginine binding, and is localized to vesicle membranes.
  • Transcriptomics analysis confirmed significant expression of NOS1, NOS2, and NOS3 in COVID-19 and pulmonary hypertension cohorts.

Conclusions:

  • Nitric oxide (NO) presents a promising therapeutic avenue for COVID-19, potentially by inhibiting viral replication and improving pulmonary function.
  • Inhaled NO may optimize ventilation-perfusion ratios and reduce the need for mechanical ventilation in COVID-19 patients.
  • Further research into NO's molecular targets and NOS isoforms is crucial for developing effective COVID-19 treatments.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
278
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
275
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
593
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
526